- Home
- KLRS vs CUE Comparison
KLRS vs CUE Comparison
Compare KLRS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CUE
- Stock Information
- Founded
- KLRS 2019
- CUE 2014
- Country
- KLRS United States
- CUE United States
- Employees
- KLRS N/A
- CUE N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- CUE Health Care
- Exchange
- KLRS Nasdaq
- CUE Nasdaq
- Market Cap
- KLRS 129.0M
- CUE 58.9M
- IPO Year
- KLRS N/A
- CUE 2018
- Fundamental
- Price
- KLRS $3.89
- CUE $0.75
- Analyst Decision
- KLRS Buy
- CUE Strong Buy
- Analyst Count
- KLRS 1
- CUE 3
- Target Price
- KLRS N/A
- CUE $3.00
- AVG Volume (30 Days)
- KLRS 62.9K
- CUE 159.5K
- Earning Date
- KLRS 05-19-2025
- CUE 05-20-2025
- Dividend Yield
- KLRS N/A
- CUE N/A
- EPS Growth
- KLRS N/A
- CUE N/A
- EPS
- KLRS N/A
- CUE N/A
- Revenue
- KLRS N/A
- CUE $9,287,000.00
- Revenue This Year
- KLRS N/A
- CUE N/A
- Revenue Next Year
- KLRS N/A
- CUE $25.99
- P/E Ratio
- KLRS N/A
- CUE N/A
- Revenue Growth
- KLRS N/A
- CUE 69.16
- 52 Week Low
- KLRS $4.19
- CUE $0.45
- 52 Week High
- KLRS $24.15
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- CUE 44.42
- Support Level
- KLRS N/A
- CUE $0.71
- Resistance Level
- KLRS N/A
- CUE $0.78
- Average True Range (ATR)
- KLRS 0.00
- CUE 0.05
- MACD
- KLRS 0.00
- CUE 0.01
- Stochastic Oscillator
- KLRS 0.00
- CUE 39.60
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.